Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.

Related Articles

Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):469-473

Authors: Burke EE, Zager JS

Abstract
INTRODUCTION: Current treatment of advanced melanoma is rapidly changing with the introduction of new and effective therapies including systemic as well as locoregional therapies. An example of one such locoregional therapy is intralesional injection with talimogene laherparepvec (T-VEC). Areas covered: T-VEC has been shown in a number of studies to be an effective treatment for patients with stage IIIB, IIIC and IVM1a melanoma. In this article the effectiveness, pharmacokinetics and safety profile of T-VEC is reviewed. Additionally, new research looking at combinations of T-VEC and systemic immunotherapies is reviewed. Expert opinion: Overall, T-VEC is an easily administered, safe, well tolerated and effective oncolytic viral therapy for the treatment of stage IIIB, IIIC, IVM1a unresectable and injectable metastatic melanoma. Recently published studies are showing promising results when T-VEC is combined with systemic therapy and this may be the way of the not too distant future in how we treat metastatic melanoma. Continued work regarding the use of T-VEC with other systemic agents will provide new and more effective treatment strategies for advanced melanoma.

PMID: 29557682 [PubMed - indexed for MEDLINE]

https://ift.tt/2u9gNsI